Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9359669 | 1.00 | SRD5A1 (0.33) | SRD5A1LMNATSHRALDH1A1PKM | |
| SCHEMBL6638258 | 0.95 | ALDH1A1 (0.36) | SRD5A1LMNATSHRALDH1A1PKM | |
| SCHEMBL8465326 | 0.95 | ALDH1A1 (0.36) | SRD5A1LMNATSHRALDH1A1PKM | |
| SCHEMBL5567030 | 0.95 | ALDH1A1 (0.36) | SRD5A1LMNATSHRALDH1A1PKM | |
| SCHEMBL3046579 | 0.95 | ALDH1A1 (0.36) | SRD5A1LMNATSHRALDH1A1PKM | |
| SCHEMBL9733421 | 0.93 | MAPT (0.35) | SRD5A1LMNATSHRALDH1A1PKM | |
| SCHEMBL9733418 | 0.93 | MAPT (0.35) | SRD5A1LMNATSHRALDH1A1PKM | |
| SCHEMBL9517429 | 0.91 | CRBN (0.35) | SRD5A1LMNATSHRALDH1A1PKM | |
| SCHEMBL26673240 | 0.88 | SRD5A1 (0.38) | SRD5A1LMNATSHRALDH1A1PKM | |
| SCHEMBL18150856 | 0.86 | SRD5A1 (0.37) | SRD5A1LMNATSHRALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114032-A1 | SUBSTITUTED UREA DERIVATIVES AND PHARMACEUTICAL USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-04-27 | — | — | US | disclosed |
| EP-0713702-B1 | ANXIOLYTIC AGENT | TAIHO PHARMACEUTICAL CO LTD (JP) | 2004-09-29 | — | — | EP | disclosed |
| US-6500819-B2 | HAS AN EXCELLENT ANXIOLYTIC EFFECT | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 2002-12-31 | — | — | US | disclosed |
| US-20020099048-A1 | Bicycloloactam compounds, use thereof and intermediates for preparing thereof | TAIHO PHARMACEUTICAL COMPANY LIMITED | 2002-07-25 | — | — | US | disclosed |
| US-6355668-B1 | ANXIOLYTIC AGENTS; SIDE EFFECT REDUCTION | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2002-03-12 | — | — | US | disclosed |
| US-6303623-B1 | TREATING ANXIETY IN A PATIENT IN NEED OF SUCH TREATMENT, COMPRISING ADMINISTERING BICYCLOLACTAM COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2001-10-16 | — | — | US | disclosed |
| US-6159987-A | Bicyclolactam compounds, use thereof and intermediates for preparing thereof | TAIHO PHARMACEUTICALS, CO. (JP) | 2000-12-12 | — | — | US | disclosed |
| US-6004975-A | ANXIOLYTIC AGENTS WITH SIDE EFFECT REDUCTION | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1999-12-21 | — | — | US | disclosed |
| EP-0713702-A1 | ANXIOLYTIC AGENT | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1996-05-29 | — | — | EP | disclosed |
| EP-0466933-B1 | BICYCLOLACTAM DERIVATIVE | TAIHO PHARMACEUTICAL CO LTD (JP) | 1995-11-22 | — | — | EP | disclosed |
| EP-0668268-A2 | Bicyclolactam derivatives for improving cerebral functions | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1995-08-23 | — | — | EP | disclosed |
| US-5214039-A | Cognition activators | TAIHO PHARMACEUTICAL CO., LIMITED (JP) | 1993-05-25 | — | — | US | disclosed |
| US-5185344-A | Improve cerebral function, activate cerebral metabolism, protect against anoxic brain damage | TAIHO PHARMACEUTICAL COMPANY, LTD. (JP) | 1993-02-09 | — | — | US | disclosed |
| EP-0466933-A1 | BICYCLOLACTAM DERIVATIVE | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1992-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114032-A1 | SUBSTITUTED UREA DERIVATIVES AND PHARMACEUTICAL USES THEREOF | ULK2, ULK3, ULK1 | SRD5A1 3104/4885LMNA 2340/4885TSHR 3190/4885 |
| US-20020099048-A1 | Bicycloloactam compounds, use thereof and intermediates for preparing thereof | CYP11B1, GABRA6, CYP11B2 | SRD5A1 913/4885LMNA 436/4885TSHR 4141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.